I think Canada for many years has strongly supported the provision of generic drugs, which indeed have all the kinds of prices I just mentioned. These are, of course, generic drugs that we are able to purchase. Many of those are now being produced in emerging economies, particularly India, but also in a number of other countries. It is very important that we continue to be able to purchase these generic drugs at the lowest possible price. That's a question the World Trade Organization has had about the TRIPS agreement.
I think we need Canada's support in protecting those rules. I understand that Canada has been quite outspoken on that for a number of years, but it is indeed very important that we maintain the principle that, for these life-saving treatments, there should not be a profit margin. They should allow generic producers to enter the market and to compete, because competition between generic producers is really what has in the end brought prices down. Prices continue to go down a little bit also because of the economies of scale and improved technology in the production of the drugs. We need to preserve that. Only that will enable us, with the resources we have, to fund these successful programs.